Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Midaglizole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 6/20 | 0.58 |
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.51 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.51 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.51 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.51 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.46 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.43 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.43 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.43 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.43 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midaglizole SCHEMBL9403180 | 1.00 | NISCH (0.72) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| Midaglizole SCHEMBL30029057 | 0.99 | NISCH (0.74) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| Midaglizole SCHEMBL114554 | 0.99 | NISCH (0.74) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7548321 | 0.91 | NISCH (0.66) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| Midaglizole SCHEMBL4783531 | 0.89 | NISCH (0.60) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7555329 | 0.86 | NISCH (0.57) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7547511 | 0.86 | NISCH (0.57) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7548764 | 0.85 | NISCH (0.56) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7547171 | 0.85 | NISCH (1.00) | NISCHMAOAMAOBTAAR1LMNA | |
| SCHEMBL7553919 | 0.84 | NISCH (0.54) | NISCHMAOAMAOBSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| US-20170136029-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-9592288-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160166687-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | THE SCRIPPS RESEARCH INSTITUTE | 2016-06-16 | — | — | US | disclosed |
| US-9101539-B2 | Intranasal pharmaceutical compositions with improved pharmacokinetics | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-8673360-B2 | Compositions that enable rapid-acting and highly absorptive intranasal administration | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20140038949-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | IRM LLC (BM) | 2014-02-06 | — | — | US | disclosed |
| EP-2675893-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | The Scripps Research Institute (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112933-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2429495-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PHARMACOKINETICS | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110033544-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PHARMACOKINETCS | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2010131486-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PHARMACOKINETICS | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2010-11-18 | — | — | WO | disclosed |
| US-20080260848-A1 | Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration | TRANSLATIONAL RESEARCH, LTD., (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1785145-A1 | TRANSNASAL COMPOSITION HAVING IMMEDIATE ACTION AND HIGH ABSORBABILITY | Translational Research, Ltd. (JP) | 2007-05-16 | — | — | EP | disclosed |